Literature DB >> 22588256

A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice.

Toshihiko Sugiura, Shunsuke Kageyama, Ayatoshi Andou, Tomoko Miyazawa, Chieko Ejima, Akira Nakayama, Taeko Dohi, Hiroyuki Eda.   

Abstract

Entities:  

Year:  2012        PMID： 22588256     DOI： 10.1124/jpet.112.193946

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN： 0022-3565            Impact factor:   4.030


× No keyword cloud information.
  3 in total

1.  Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis.

Authors:  Qing Chen; Joan Massagué
Journal:  Clin Cancer Res       Date:  2012-08-09       Impact factor: 12.531

Review 2.  Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.

Authors:  Saskia Thomas; Daniel C Baumgart
Journal:  Inflammopharmacology       Date:  2011-12-20       Impact factor: 4.473

Review 3.  Integrin-based therapeutics: biological basis, clinical use and new drugs.

Authors:  Klaus Ley; Jesus Rivera-Nieves; William J Sandborn; Sanford Shattil
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.